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Background: One of the purposes of treatment for dogs with mitral regurgitation (MR) is lowering left atrial
pressure (LAP). There has been few study of the amlodipine in dogs with MR and amlodipine’s effect on LAP has
not been fully evaluated in a quantitative manner because of difficulties in directly measuring LAP. The objective of
our study was to compare the short-term effects of amlodipine (0.2 mg/kg PO q12h) vs benazepril (0.5 mg/kg PO
q12h), on LAP and echocardiographic parameters in five beagle dogs with experimentally-induced MR. LAP of eight
dogs that has own control were measured using radiotelemetry system at baseline and again on days 1, 2, 3, 4, 5,
6, 7 of the drug administration.
Results: Mean LAP decreased significantly after amlodipine (11.20 ± 4.19 mmHg vs 14.61 ± 3.81 mmHg at baseline,
p < .01) but not after benazepril treatment (13.19 ± 3.47 mmHg, p > .05). LAP was lower after 7 days of amlodipine
treatment than after 7 days of benazepril treatment. Significant reduction was seen for the first time 4 days after
the administration amlodipine. The rate of the maximal area of the regurgitant jet signals to the left atrium area
(ARJ/LAA) of the amlodipine treatment was significantly lower (p < .05) after 7 days compared to baseline. Other
echocardiographic parameters did not change significantly.
Conclusions: LAP was significantly decreased after amlodipine treatment in dogs with surgically-induced MR but
not after benazepril treatment. Although this study did not focus on adverse effects, amlodipine may be an
effective drug for helping the patients with acute onset of severe MR, such as rupture of chordae tendinae or end
stage patients were the LAP is likely to be elevated. Additional studies in clinical patients with degenerative mitral
valve disease and acute chordal rupture are warranted because the blood-pressure lowering effects of amlodipine
can decrease renal perfusion and this can further activate the RAAS.Background
Mitral valve disease (MVD) is the most common cardiac
disease in dogs. Moreover, as many as 75% of all dogs with
signs of congestive heart failure suffer from mitral regurgi-
tation (MR) caused by myxomatous degeneration of the
valve leaflets or chordae tendineae [1,2]. Left atrial compli-
ance maintains a relatively normal left atrial pressure
(LAP) in dogs with MR [3]. However, if left atrial compli-
ance decrease, LAP will increase. Increased LAP causes
pulmonary edema, which can lead to cough, dyspnea, and
even death [4]. Reduction of LAP is a desirable goal for* Correspondence: ryo@vet.ne.jp
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reproduction in any medium, provided the ordrugs used to treat congestive heart failure in MVD. In
general, calcium channel blockers are used for treatment of
hypertrophic cardiomyopathy [5-7], atrial fibrillation [8-
10], and systemic hypertension [11,12]. Amlodipine is a
long acting 1,4-dihydropyridine calcium channel blocker,
often used for treatment of systemic hypertension. Sys-
temic hypertension is defined as an increase of systolic and
or diastolic blood pressure and common in dogs with renal
disease and in aged and hyperthyroid cats [5]. In dogs with
MR, amlodipine increases forward flow with afterload re-
duction because of the reduction in systemic vascular re-
sistance [5,13]. Therefore, in theory, amlodipine are
thought to decrease the volume of regurgitation across an
insufficient valve and LAP. However, there has been fewLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The scheme of left atrial pressure measurement by a
radio telemetry system in this experiment. The digital signal of
the data of the left atrial pressure from the transmitter was sensed
by the receiver and sent to a data exchange matrix. An ambient
pressure reference monitor was connected to the data exchange
matrix to monitor correct atmospheric pressure and exclude all rocal
environmental pressure fluctuations. Finally, the digital signal data
was converted to an analog signal by the data exchange matrix and
sent to a personal computer.
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effect on LAP has not been fully evaluated in a quantitative
manner because of difficulties in directly measuring LAP.
We have previously used a radiotelemetry system to report
the effects of angiotensin-converting enzyme (ACE) inhibi-
tors and furosemide in dogs with experimentally-induced
MR [14-16], and we believe this system would be useful for
evaluation of hemodynamic changes after administration
of amlodipine.
In the present study, we used a radio telemetry system
to monitor LAP in dogs with experimentally induced
MR and evaluated the effects of amlodipine. Also we
evaluated echocardiography, blood pressure (BP), and




Before starting the study, the health of five 2-year-old Bea-
gle dogs (2 males and 3 females) weighing 12.4 ± 2.4 kg
(range: 10.2 to 15.2 kg) was evaluated by general clinical
examination, blood and serum bio chemical examinations,
electrocardiography, thoracic radiography, and echocardi-
ography. All dogs were acclimatized to the experimental
environment and human handling. During all phases of
the study, the dogs were managed and cared for in accord-
ance with the standards established by the Tokyo Univer-
sity of Agriculture and Technology (TUAT) and described
in its “Guide for the Care and Use of Laboratory Animals.”
This study was approved by the Experimental Animal
Committee of TUAT (acceptance no. 21–19).
MR and transmitter implantation
Dogs were premedicated with meloxicam (Boehringer
Ingelheim Vetmedica Japan, Hyogo, Japan) (0.2 mg/kg SC),
atropine sulfate (Tanabe Seiyaku Co., Ltd., Osaka, Japan)
(0.04 mg/kg SC), butorphanol tartrate (Meiji Seika kaisha
Ltd., Tokyo, Japan) (0.2 mg/kg IV), and midazolam hydro-
chloride (Astellas Pharma Inc., Tokyo,Japan) (0.2 mg/kg
IV). Induction was achieved with propofol (Schering-
Plough, Tokyo, Japan) (4 mg/kg IV), after which the dog
was intubated. General anesthesia was maintained with in-
halation of isoflurane (Dainippon Sumitomo Pharma Co.,
Ltd., Osaka, Japan) mixed with oxygen. A left lateral thora-
cotomy was performed at the fifth intercostal space and
the pericardium was opened by standard procedures. The
left atrium was purse-string sutured with 3–0 nylon and a
small incision was made at the center of the purse-string
suture. The suture then was loosened and 5-in. curved
Halsted mosquito forceps were inserted through the small
incision to grasp and rupture the mitral valvular chordae
tendineae. The position of the chordae tendineae and the
degree of induced MR were monitored by transesophageal
echocardiography and these procedures were repeateduntil visible MR was identified without any manual ma-
nipulation. The telemetry transmitter catheter (Data
Sciences International, St. Paul, MN, USA) then was
inserted 1 cm into the small incision and the catheter was
fixed to the left atrium with a suture. The telemetry trans-
mitter body was implanted under the triceps brachii
muscle and the catheter was fixed to abdominal trunk
muscles with 3–0 nylon suture. The chest then was closed
in layers and air was evacuated by standard procedures.
Postoperatively, cefamedin (Astellas Pharma Inc.) was
administered (50 mg/kg/day IV or PO) for 7 days and post-
operative pain was treated with meloxicam (0.1 mg/kg SC)
for 3 days. Thoracic radiography and echocardiography
were performed to evaluate pulmonary venous congestion
and cardiac dilatation. After the radiotelemetry transmitter
implantation, the dogs were rested for at least 5 weeks,
until no major variations were identified in echocardio-
graphic evaluation and LAP.
Drug administration and LAP measurement
Amlodipine (Dainippon Sumitomo Pharma) of 0.2 mg/kg
was administered PO q12h or benazepril (Novartis Pharma
K.K., Tokyo, Japan) of 0.5 mg/kg was administered PO
q12h to 5 dogs for 7 days. After a 7-day washout period,
the other drug was administered for 7 days, using a cross-
over study method. All radiotelemetry systems (Data
Sciences International) and recording procedures were the
same as those described in a previous report [14]. The
maximum, mean, and minimum LAP were obtained as the
averages of 10-second segments from continuous wave-
form recordings (Figure 1) [17,18]. LAP was measured for
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days 1, 2, 3, 4, 5, 6, 7 of the drug administration. The sam-
pling frequency was every 10 seconds.
Echocardiography
Before and after administration of each drug, echocar-
diographic measurements were performed along with
blood pressure and LAP measurements. A single investi-
gator performed transthoracic conventional echocardi-
ography as well as 2-dimensional spectral Doppler and
tissue Doppler echocardiography. Each dog was posi-
tioned in left and right recumbency, with echocardio-
graphic examinations performed by means of a digital
ultrasonographic system (Aloka Co., Ltd., Tokyo, Japan)
with a 5.0 MHz sector transducer. Sweep speed during
the Doppler and M-mode recordings was 150 to
200 mm/sec. Right parasternal views were used to meas-
ure heart dimensions. LA/Ao was assessed in a right
parasternal short-axis view of the heart base for asses-
sing LA enlargement [19]. We measured the internal
diameter of the aorta along the commissure between the
noncoronary and right coronary aortic valve cusp and
internal diameter of the left atrium in a line extending
from and parallel to the commissure between the non-
coronary and left coronary aortic valve cusp to the dis-
tant margin of the left atrium on the 1st frame after
aortic valve closure. A short axis M-mode view at the
chordal level was used to measure left ventricular end-
diastolic diameter (LVEDD). Left apical views of the left
ventricular inflow and outflow tracts were used to meas-
ure mitral inflow and aortic flow using a pulsed wave
sample volume of 4 mm. Forward stroke volume (SV)
and cardiac output (CO) were calculated by use of a left
ventricular outflow view. SV was calculated as SV=velocity
time integral (VTI)× cross-sectional area (CSA). CO was
calculated as CO=SV×HR. The systolic (Sa) and early
diastolic (Ea) myocardial velocities by pulsed tissue Dop-
pler imaging (TDI) were measured at lateral mitral annulus
in the left apical views. Peak transmitral early diastolic
wave (E wave) velocity and atrial contraction wave (A
wave) were measured from Doppler signals of the mitral
inflow, and E/A, E/Ea were calculated. MR flow was
recorded using the 2-chamber view with a high-intensity
continuous wave spectral Doppler signal, and MR pressure
gradient was calculated based on a modified Bernoulli’s
equation, ΔP=4(MR velocity)2. The measurements of the
maximal area of the regurgitant jet signals (ARJ) was per-
formed in the apical 4-chamber view, the left atrium area
(LAA) also was measured in the same frame in the which
the maximal ARJ was seen, and ARJ/LAA was calculated.
Maximum color Doppler velocity was set at 66 cm/s. Color
gain was decreased until background noise just disap-
peared [20]. All echocardiographic variables were averaged
from 5 consecutive beats. All of the echocardiographicrecordings were stored on the internal hard drive of the
echocardiograph and transmitted to the DICOM server
online (ImageONE Co., Ltd., Tokyo, Japan).
Blood pressure measurements
All indirect arterial BP recordings were obtained by the
oscillometric method (Fukuda ME, Tokyo, Japan). Cuff
size width was set to approximately 40% of tail circum-
ference for each dog [21]. BP measurements were per-
formed simultaneously with echocardiography for MR
velocity measurements, and 5 consecutive measurements
were averaged for each dog for use in the calculations.
Systemic vascular resistance (SVR) was calculated as
SVR= 79.9 × (Mean BP-Central venous pressure)/CO
[22], and Cemtral venous pressure was defined as
5 mmHg due to a lack of right-sided heart failure signs,
jugular distension, or positive hepatojugular reflex.
Statistical analysis
All data are represented as mean plus or minus standard
deviation (SD). All data were normally distributed. A 1-way
repeated measures analysis of variance (ANOVA) in con-
junction with a Bonferroni’s multiple comparison test was
used for comparing LAP and echocardiographic variables
before and 7 days after administration of each dose. A
2-way repeated measures ANOVA in conjunction with a
Bonferroni’s multiple comparison test was used to com-
pare LAP of each day after the administration of amlodi-
pine. Statistical significance was defined as p< .05.
GraphPad Prism version 5.0a (GraphPad, San Diego, CA,
USA) and EXCEL 2008 (Microsoft, Redmond, WA,
USA) were used to perform these statistical analyses.
Results
LAP and blood pressure
All dogs were stage B2 in guidelines for the diagnosis
and treatment of canine chronic valvular heart dis-
ease of the American College of Veterinary Internal
Medicine (ACVIM) classification [23]. No obvious
adverse effects were observed during periods of the
drug administration.
Mean LAP decreased significantly after the administration
of amlodipine (14.61±3.81 mmHg to 11.20±4.19 mmHg,
p< .01), as shown in Figure 2. Similarly, Mean LAP
decreased after the administration of benazepril, however,
there was no significant difference (14.53±3.92 mmHg to
13.19±3.47 mmHg, p> .05). Also, LAP was lower after
7 days of amlodipine treatment than after 7 days of benaze-
pril treatment (p< .05).
Statistically significant reduction of LAP was first
observed 4 days after the administration of amlodipine,
as shown in Figure 3. Similarly, significant reduction of
SBP was first observed 4 days after the administration of
amlodipine. SBP and MBP of both the amlodipine and
Figure 2 Left atrial pressure 7 days after administration of
amlodipine. Left atrial pressure (LAP) 7 days after administration of
amlodipine 0.2 mg/kg or benazepril 0.5 mg/kg q12h PO in 5 dogs
with MR. Baseline values were those obtained before drug
administration. The box and whiskers plot demonstrates the mean
(+), the median (line), 5 and 95% confidence limits (box) and range
(bars). *P < .05, **P < .01.
Figure 3 Temporal variation after administration of amlodipine.
Temporal variation of Mean LAP and Systolic blood pressure after
administration of amlodipine in 5 dogs with MR. *Significant
differences (P < .05) compared with each baseline.
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to baseline, as shown in Figure 4. Also, SBP was lower
after 7 days of amlodipine treatment than after 7 days of
benazepril treatment, however, there was no significantly
difference. HR of both the amlodipine and the benaze-
pril treatment did not change significantly as shown in
Figure 4.
Echocardiography and hemodynamic parameters
ARJ/LAA was significantly lower after 7 days of amlodipine
treatment than baseline (p < .05), as shown in Figure 5. As
shown in Table 1, other echocardiographic parameters did
not change significantly. SV and CO of the amlodipine
treatment increased significantly compared to baseline, as
shown in Figure 6. SVR of amlodipine treatment decreased
significantly compared to baseline, as shown in Figure 7.
Discussion
This study had a number of important findings. Firstly,
LAP was significantly decreased with amlodipine in dogs
with MR. Secondly, LAP appeared to decrease according
to the decreasing in SBP and MBP. Thirdly, stroke vol-
ume and cardiac output increased and systemic vascular
resistance decreased after administration of amlodipine.
Finally, the severity of mitral regurgitation appeared to
decrease according to the reduction in ARJ/LAA.
In a previous report, amlodipine decreased left ven-
tricular end-diastolic pressure (measured as a surrogate
for LAP) in dogs with pacing-induced heart failure [13].
However, there are few studies that the effect ofamlodipine on left atrial pressure in dogs with MR. In
the present study, LAP was significantly decreased and
cardiac output was significantly increased by amlodipine
in dogs with MR (Figures 2 and 6). Amlodipine is arter-
ial vasodilators and used to reduce systemic vascular re-
sistance in patients with cardiac heart failure [5]. The
reduction in systemic vascular resistance results in an
increase in cardiac output. In dogs with MR, amlodipine
increases cardiac out put, therefore, decreases the vol-
ume of regurgitation relatively across a mitral valve. So,
our results suggest amlodipine has beneficial effect on
LAP in dogs with MR. Also, in the present study, ad-
verse effects of amlodipine were not observed but we
feel this warrants further examination because there is a
report that long-term administration of amlodipine to
dogs with mitral regurgitation may cause gingival hyper-
plasia in a small percentage of patients [24].
Both of the amlodipine and benazepril are classified of
vasodilators based on mechanism of action. Amlodipine
was more effective than ACE inhibitor in lowering blood
pressure [25]. In our previous report, an ACE inhibitor
Figure 4 Systolic blood pressure Mean blood pressure and Heart rate 7 days after administration of amlodipine. Systolic blood pressure
(SBP), Mean blood pressure (MBP) and Heart rate (HR) 7 days after administration of amlodipine 0.2 mg/kg or benazepril 0.5 mg/kg q12h PO in 5
dogs with MR. Baseline values were those obtained before drug administration. The box and whiskers plot demonstrates the mean (+), the
median (line), 5 and 95% confidence limits (box) and range (bars). *P < .05, **P < .01.
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afterload [14]. Conversely, in the present study, amlodipine
significantly decreased LAP, as well as SVR (Figure 7). This
result suggests that strong reduction in afterload is asso-
ciated with the decrease in LAP. Patients with heart failure
need to maintain an adequate kidney perfusion and lower-
ing the blood pressure per se can just induce renal failure
(cardio-renal syndrome). So, while it is likely that amlodi-
pine is an effective drug for helping the patients with acute
onset of severe MR (i.e. rupture of chordae tendinae) or
end stage patients were the LAP is likely to be elevated, the
same cannot be true in patients stable chronic heart failure.
It is thought that the positive long term benefits for
patients treated with ACE inhibitor are related to their
ability to block the Renin-Angiotensin-Aldosterone system
(RAAS) more than to their vasodilation properties. On the
other hand, indication of Amlodipine may be limitedFigure 5 ARJ/LAA 7 days after administration of amlodipine.
The ratio of the maximum area of the regurgitant jet signals to the
left atrium area (ARJ/LAA) 7 days after administration of amlodipine
0.2 mg/kg or benazepril 0.5 mg/kg q12h PO in 5 dogs with MR.
Baseline values were those obtained before drug administration. The
box and whiskers plot demonstrates the mean (+), the median (line),
5 and 95% confidence limits (box) and range (bars). *P < .05.because the blood-pressure lowering effects of amlodipine
can decrease renal perfusion and this can further activate
the RAAS.
Amlodipine significantly decreased MBP and increased
HR, although not statistically significant in previous reports
[25]. Similarly, in the present study, amlodipine decreased
MBP but did not change HR. The published dosage data in
dogs is from 0.05 mg/kg/day [5] to 1 mg/kg/day [26]. The
high end of this range (approximately 1 mg/kg/day) was
chosen in the previous report [25]. However, in the present
study, the dosage was 0.2 mg/kg q12h and HR might not
have changed after administration of amlodipine. Further
examination would be needed for the detailed information
for the amlodipine dosage for dogs with MR.
There is a report on echocardiographic values of cats
with systemic hypertension after administration of amlo-
dipine [12]. However, no difference was found in any of
the echocardiographic measurements between the un-
treated and treated cats in the previous report. In the
present study, only ARJ/LAA of the amlodipine groupTable 1 Comparison of echocardiographic parameters
after the drug administration
Variable Baseline Amlodipine Benazepril
LVEDD (cm) 3.77 ± 0.33 3.65 ± 0.25 3.58 ± 0.36
LVESD (cm) 2.30 ± 0.15 2.09 ± 0.20 2.16 ± 0.27
%FS 38.7 ± 4.68 41.7 ± 6.00 39.8 ± 7.02
LA/Ao 1.54 ± 0.29 1.51 ± 0.17 1.60 ± 0.14
E wave (m/sec) 0.85 ± 0.13 0.81 ± 0.08 0.82 ± 0.10
E/A 1.79 ± 0.56 1.70 ± 0.21 1.76 ± 0.70
E/Ea 7.33 ± 1.58 7.16 ± 1.68 7.45 ± 1.72
Sa (cm/sec) 10.04 ± 1.07 12.72 ± 3.26 11.29 ± 2.62
MRPG (mmHg) 125.0 ± 12.5 130.6 ± 13.0 125.5 ± 10.8
See materials and methods section for the technique of measuring
echocardiographic parameters. LVEDD, left ventricular internal diameter in the
diastolic period; LVESD, left ventricular internal diameter in the systolic period;
%FS, fractional shortening; LA/Ao, the ratio of left atrial diameter to aortic root
diameter; E wave, transmitral early diastolic wave velocity; E/A, the ratio of
transmitral early diastolic wave velocity to atrial contraction wave velocity; E/
Ea, the ratio of transmitral early diastolic wave velocity to lateral mitral annulus
velocity in the early diastolic period; Sa, lateral mitral annulus velocity in the
systolic period; MRPG, mitral regurgitation pressure gradient.
Figure 6 Stroke volume and Cardiac output 7 days after administration of amlodipine. Stroke volume (SV) and Cardiac output (CO) 7 days
after administration of amlodipine 0.2 mg/kg or benazepril 0.5 mg/kg q12h PO in 5 dogs with MR. The box and whiskers plot demonstrates the
mean (+), the median (line), 5 and 95% confidence limits (box) and range (bars). *P < .05.
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Other echocardiographic parameters did not change sig-
nificantly. We previously have reported that E wave and
E/Ea can be used for the evaluation of preload after ad-
ministration of high doses of furosemide, and have mon-
itored the reduction of LAP in the short-term [16].
However, present study suggests that it is difficult to
evaluate the reduction of LAP after administration of
amlodipine by using E wave and E/Ea. E, E/A and E/Ea
are influenced not only by preload but relaxation, com-
pliance, and heart rate [27]. Again it is the left atrial
compliance that plays a major role in changing LAP.
The echocardiographic indices might not have changed
in this study because the left atrial compliance had been
maintained despite the fluctuation of LAP. Conversely,
ARJ/LAA, SBP and MBP may be useful to evaluation
after administration of amlodipine.Figure 7 Systemic vascular resistance 7 days after
administration of amlodipine. Systemic vascular resistance (SVR)
7 days after administration of amlodipine 0.2 mg/kg or benazepril
0.5 mg/kg q12h PO in 5 dogs with MR. The box and whiskers plot
demonstrates the mean (+), the median (line), 5 and 95%
confidence limits (box) and range (bars). **P < .01.Amlodipine is recommended at dosages of 0.05 mg/
kg/day to 1 mg/kg/day for dogs [5,26]. However, the op-
timal dosage for dogs with MR is not known. This study
was not designed to evaluate the optimal dosage of
amlodipine for dogs with MR. Therefore, it may have
some adverse effects by dosage. Also, toxic effects are
not known with longterm administration of amlodipine
in asymptomatic dogs because this study is shortterm
study using dogs with experimentally-induced MR. In
the present study, five 2-year-old Beagle dogs were used
and a 5-week period was defined as a subchronic period
for experimentally-induced MR. In clinical situations,
dogs with MR and cardiac dysfunction and myocardial
tissue damage might differ from the model dogs in this
study. Therefore, our model may more closely resemble
acute MR and differ from naturally-occurring chronic
MR. SV and CO were calculated by echocardiography.
Therefore, it may differ from the value strictly measured
with the catheter.
In the present study, the neurohormonal response to
treatment was not studied. Therefore, if a pure vasodila-
tor is used to decrease blood pressure, there is a risk of
a deleterious neurohormonal activation leading for ex-
ample in increased heart rate.
Conclusions
LAP was significantly decreased with amlodipine treat-
ment in dogs with surgically-induced MR, while LAP
was not significantly decreased with benazepril treat-
ment. Although this study did not focus on adverse
effects, amlodipine may be an effective drug for help-
ing the patients with acute onset of severe MR such
as rupture of chordae tendinae or end stage patients
were the LAP is likely to be elevated. Additional stud-
ies in clinical patients with degenerative mitral valve
disease and acute chordal rupture are warranted be-
cause the blood-pressure lowering effects of amlodi-
pine can decrease renal perfusion and this can further
activate the RAAS.
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